European Cooperative Acute Stroke Study-4: Extending the time for thrombolysis in emergency neurological deficits ECASS-4: ExTEND
Hemasse Amiri, Erich Bluhmki, Martin Bendszus, Christoph C Eschenfelder, Geoffrey A Donnan, Didier Leys, Carlos Molina, Peter A Ringleb, Peter D Schellinger, Stefan Schwab, Danilo Toni, Nils Wahlgren, Werner Hacke
INTERNATIONAL JOURNAL OF STROKE | SAGE PUBLICATIONS LTD | Published : 2016
RATIONALE AND HYPOTHESIS: Thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) is an effective and approved therapy for acute ischemic stroke within 4.5 h of onset except for USA, Canada, Croatia, and Moldovia with a current 3 h label. We hypothesized that ischemic stroke patients selected with significant penumbral mismatch on magnetic resonance imaging (MRI) at 4.5-9 h after onset of stroke will have improved clinical outcomes when given intravenous rt-PA (alteplase) compared to placebo. STUDY DESIGN: ECASS-4: ExTEND is an investigator driven, phase 3, randomized, multi-center, double-blind, placebo-controlled study. Ischemic stroke patients presenting within 4.5 and ..View full abstract
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: ECASS-4: ExTEND is an investigator driven trial supported with an unrestricted grant from Boehringer Ingelheim (Germany).